PFBC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PFBC is not a good buy right now. The stock is trading near key support (~83.46) and is technically oversold, but the broader near-term setup remains weak (bearish momentum still present, negative pattern-based probabilities for the week/month, and bearish options positioning). With no fresh news catalysts and analysts cutting targets post-earnings, the risk of further downside or dead-money trading outweighs the potential for a quick upside move for an impatient buyer.
PFBC is in a short-term downtrend/weak phase. The MACD histogram is negative (-1.562), showing bearish momentum, though it is contracting, which can indicate selling pressure is easing. RSI(6) at 26.6 signals oversold conditions (bounce potential), but oversold alone is not a reliable buy trigger without confirmation. Price at 83.85 is sitting just above S1 support (83.463); a breakdown would put S2 (79.137) in play. Upside resistance is heavy with the pivot at 90.465 and R1 at 97.467, meaning any rebound likely faces overhead supply before turning into a sustained uptrend. Candlestick-pattern analogs imply modest upside next day (+0.71%) but negative odds over the next week/month (~-3.8%), consistent with a fragile setup.
Oversold technical condition (RSI(
~26.
near S1 support can spark a short-term bounce.
Latest reported quarter (2025/Q
showed solid bottom-line growth (Net Income +15.22% YoY, EPS +24% YoY), which can provide fundamental support on dips.
Piper Sandler maintains an Overweight rating with a still-meaningful price target ($111), implying upside if bank sentiment improves.
Post-earnings analyst target cuts (Stephens $105→$93; Piper Sandler $121→$
reflect a weaker outlook, especially around NII/NIM.
Stephens explicitly flags criticized-loan risk as a potential headwind and sees limited valuation-catalyst path.
Bearish options open-interest skew (high put/call OI) suggests investors are positioned defensively.
No new news/catalysts in the past week to change sentiment.
Pattern-based expectations skew negative over the next week/month (~-3.8%).
Latest quarter: 2025/Q4. Revenue increased to $73.15M (+1.57% YoY), while profitability improved more meaningfully: Net Income $34.82M (+15.22% YoY) and EPS $2.79 (+24.00% YoY). This indicates improving earnings power despite modest top-line growth, but the market’s focus appears to be shifting toward forward net interest margin/income pressure and credit quality risk.
Recent trend is cautious: both highlighted firms lowered price targets after earnings. Stephens reiterated Equal Weight and cut PT to $93 (from $105), citing limited valuation catalysts and potential criticized-loan headwinds. Piper Sandler kept Overweight but cut PT to $111 (from $121) and reduced 2026/2027 EPS estimates due to a lower NII/NIM outlook. Wall Street pros/cons view: Pros—one Overweight rating remains and targets still imply upside from ~83.85. Cons—targets are being revised downward, and credit quality/NIM concerns are explicitly noted, which tends to cap near-term multiple expansion.
